Background Tacrolimus is an approved first-line immunosuppressive agent for kidney
transplantations. Part of interindividual and interethnic differences in the response of …

Tacrolimus is a commonly used immunosuppressant after kidney transplantation. It has a
narrow therapeutic range and demonstrates wide interindividual variability in …

Background. Tacrolimus is a major immunosuppressant, which has a narrow therapeutic
range and wide interindividual variation. The effects of genetic polymorphisms of …

Previously, we reported that, at 3 months after renal transplantation, individuals with
CYP3AP1 genotype CYP3AP1* 1 (linked to CYP3A5* 1 and strongly associated with …

OBJECTIVE: Tacrolimus concentrations are associated with CYP3A5 genotype. The
purpose of this study was to evaluate the outcomes and drug concentrations/doses among a …

Aim: Meta-analyses and large cohort studies provide confusing results on the association of
the CYP3A5 6986A> G allelic variant and adverse outcomes in kidney transplant recipients …

Objectives: The aims of this study were to develop a population pharmacokinetic model of
tacrolimus in adult kidney transplant recipients, to use this model to compare cytochrome …

Background Suboptimal immunosuppression after kidney transplantation contributes to
toxicity and loss of efficacy. Little is known regarding the impact of intra‐patient variability of …

Purpose The purpose of this study is to determine the impacts of CYP3A5 polymorphism on
tacrolimus concentration and the proportion of patients within a target therapeutic range …

Tacrolimus is metabolized by CYP3A4 and CYP3A5 enzymes. Patients expressing CYP3A5
(in Caucasian patients about 15% of the population but more frequent in African Americans …